RxDoctor Payments DataLook up a doctor →

Steven Ugent, MD

Dermatology · Plainville, MANPI 1417050436

Payments from drug & device makers

$137,739in general payments, 2019–2025

Across 753 payments — averaging $182.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$83K
  • Amgen$22K
  • Lilly USA, LLC$14K
  • Bristol Myers Squibb$9K
  • Novartis$4K
  • Johnson & Johnson$2K
  • plus $4K from 21 others

What the payments were for

  • Consulting fees$2,6702%
  • Speaking & faculty fees$117,99586%
  • Travel & lodging$3,4312%
  • Food & beverage$13,32910%
  • Education$3140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$137,739 in reported general payments places this provider in the 90th percentile of 552 dermatology providers in Massachusetts.

See all dermatology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$154,184
Medicare patients
611
Services billed
2,324

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa11$231,306
OtezlaApremilast31$144,009
Dupixent PenDupilumab17$63,591
JubliaEfinaconazole17$13,727
Clobetasol Propionate52$2,842
Acitretin13$2,296
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc47$2,203
Tacrolimus13$1,680
Clindamycin Phosphate27$1,293
Doxycycline Hyclate79$1,280
Mometasone Furoate42$1,115
Triamcinolone Acetonide93$1,031
Ketoconazole51$943
CiclopiroxCiclopirox Olamine43$788
Fluorouracil13$741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$21,836$144,00931 claims
Ortho Dermatologics, A Division Of Bausch Health US, LLCJublia$181$13,72717 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 552 dermatology providers in Massachusetts.

Other dermatology in Plainville

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →